Berton D, Pautier P, Lorusso D, Gennigens C, et al. Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I stud Gynecol Oncol 2024;186:191-198.
PMID: 38824752